Loading market dashboard
iShares Biotechnology ETF
IBBFinancial ServicesNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
LONDON--(BUSINESS WIRE)---- $IBB #AVLSOM3--AV Laboratories, a science-led skincare company founded by pioneers in IVF solutions, regenerative medicine, and stem cell therapy, today announced it will exhibit at the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE 2026, taking place in London from 5 - 8 July 2026. The company will welcome clinicians, embryologists, fertility specialists, researchers, partners, and industry participants at Booth A22. “ESHRE is deeply personal.
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.
Locking in profits while you have them can help avoid downturns.
Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange traded fund launched on June 19, 2006.
The iShares Biotechnology ETF (IBB) was launched on 02/05/2001, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Biotech has reasserted itself over the past year as drug approvals,
Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.
Assetmark Inc. grew its holdings in shares of iShares Biotechnology ETF (NASDAQ: IBB) by 150,979.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,029 shares of the financial services provider's stock after purchasing an additional 73,980 shares during
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded.
The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which has made huge strides, with semiconductors exceeding +60%. However, the biotech sector has gained +33-35% in the same period - and many predict things are just getting started. For those seeking a broad biotech exposure,... Biotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still Ahead.
The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which has made huge strides, with semiconductors exceeding +60%.
Focused on therapies for rare skin diseases, this clinical-stage biotech saw a notable director purchase coincide with a decisive Phase 3 trial announcement and the closing of a $230 million equity offering.
DAFNA Capital Management LLC sold 34,405 shares of iShares Biotechnology ETF (IBB) Quarter-end position value decreased by $3.31 million, reflecting both trading and stock price effects Trade represented a 1.3% reduction of 13F reportable assets under management Post-trade holding: 68,095 shares valued at $11.49 million IBB accounted for 2.67% of fund AUM after the trade, placing it outside the fund's top five holdings
Bank of America Corp DE lowered its position in iShares Biotechnology ETF (NASDAQ: IBB) by 4.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,893,841 shares of the financial services provider's stock after selling 243,108 shares during the
IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.
